Table 1

LC90 values of neuroblastoma and HPV 16E6 transfected clones of SMS-SAN and SMS-LHN cell lines

Phase of therapyLC90 values (μg/ml)a
cell linesL-PAMbCBDCAcETOPd
Sensitive cell lines:DXeSK-N-BE(1)0.80.20.2
DXSMS-SAN1.30.70.1
DXCHLA-1221.60.10.1
PD-IndcfSMS-LHN2.11.32.1
PD-IndcSMS-KCNR1.01.2<0.1
PD-BMTgCHLA-80.32.3<0.1
PD-BMTCHLA-512.22.6<0.1
Resistant cell lines:PD-IndihSK-N-BE(2)24.02.11.1
PD-IndiSK-N-RA37.5>10.0181.5
PD-IndiLA-N-615.48.627.3
PD-IndiCHLA-1197.46.620.5
PD-IndiCHLA-17168.911.6443.6
PD-IndiCHLA-2258.42.40.5
PD-BMTCHLA-795.03.212.6
PD-BMTCHLA-90375.013.851.3
PD-BMTCHLA-13437.126.3256.0
PD-BMTCHLA-13617.02.656.7
PD-BMTCHLA-172101.443.431.2
Transduced clones:SAN-LXSNi1.81.30.7
SAN/EG D4j8.319.629.1
SAN/E6 B3j10.831.7110.4
LHN/LXSNi4.76.43.7
LHN/E6 2–6j13.152.57.6
LHN/E6 5-B5j32.1693.5166.2
  • a Drug concentration that was cytotoxic for 90% of treated cells.

  • b Melphalan (Reference drug level for resistance defined as 3 × mean of LC90 values of cell lines established at diagnosis = 3.7 μg/ml).

  • c Carboplatin (Reference drug level for resistance = 1 μg/ml).

  • d Etoposide (Reference drug level for resistance = 0.4 μg/ml).

  • e Cell lines established from the patients before treatment.

  • f Cell lines established from patients at the time of disease progression after dual-agent induction chemotherapy.

  • g Cell lines established from patients at the time of disease progression after marrow ablative chemoradiotherapy followed by bone marrow transplantation.

  • h Cell lines established from patients at the time of disease progression after intensive multiagent chemotherapy.

  • i Empty vector controls of SMS-SAN and SMS-LHN cell lines.

  • j HPV 16 E6 clones of SMS-SAN and SMS-LHN cell lines.